Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
BMJ Open|June 2, 2019
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE studyJohannes Oldenburg, Charles R M Hay, Víctor Jiménez-Yuste, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2023
Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO RegistryCharles R M Hay, Michael Makris, Midori Shima, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|November 9, 2018
Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER studyMartin J Scott, Hua Xiang, Daniel P Hart, et al.Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|July 5, 2012
Difficult clinical challenges in haemophilia: international experiential perspectivesAngela L Forsyth, Paul Giangrande, Charles R M Hay, et al.Expert Opinion on Biological Therapy|February 17, 2009
Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia AAmy Shapiro, Ralph Gruppo, Ingrid Pabinger, et al.Blood|October 24, 2014
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Peter W Collins, Benedict P Palmer, Elizabeth A Chalmers, et al.Blood|October 19, 2006
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' OrganisationPeter W Collins, Sybil Hirsch, Trevor P Baglin, et al.Blood|April 18, 2009
A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3Megan S Sutherland, Anthony M Cumming, Mackenzie Bowman, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.Pageof 3